Therapeutic paradigm of anti-CD19 antibody therapy

By increasing the dose of CD19 antibodies and adjusting the frequency of administration, the clinical consultation frequency and hospital infection risk of patients with CD19 expression cancer are reduced, and the problem of high frequency of administration in existing treatment plans is solved, making it safer and more effective Treatment effect.

CN119013293APending Publication Date: 2024-11-22INCYTE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280090874.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-22
Filing Date
2022-12-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing CD19 antibody treatment regimen is high in the treatment of cancer patients with CD19 expression, resulting in an increase in patient burden and an increase in hospital infection risk. It is difficult for existing methods to effectively reduce adverse reactions.

Method used

Using a CD19 antibody dose of at least 24 mg/kg, reduce the frequency of administration from once a week to every two weeks, every 4 weeks or even every 8 weeks, combined with intravenous infusion forms, reduce the number and time of infusions and reduce the Patients’ clinical consultation frequency and hospital infection risk.

Benefits of technology

It significantly reduces the frequency of clinical consultations in patients, reduces the risk of hospital infection, supports long-term treatment compliance, and reduces the adverse effects of CD19 antibodies while maintaining or improving treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976423050000271
    Figure BDA0004976423050000271
  • Figure BDA0004976423050000381
    Figure BDA0004976423050000381
  • Figure BDA0004976423050000391
    Figure BDA0004976423050000391
Patent Text Reader

Abstract

The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibodies are administered to cancer patients in specific doses or dosing regimens.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure provides a therapy comprising an anti-CD19 antibody for treating various cancers. Background Art

[0002] B cells are lymphocytes that play a greater role in humoral immune responses. They are produced in the bone marrow of most mammals and account for 5-15% of the circulating lymphatic pool. The main function of B cells is to produce antibodies against various antigens and is an essential component of the adaptive immune system. Due to its key role in immune system regulation, the imbalance of B cells is associated with various conditions such as cancer. These include lymphomas and leukemias such as non-Hodgkin's lymphoma (non-Hodgkin's lymphoma, NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute lymphoblastic leukemia (ALL).

[0003] NHL is a heterogeneous malignancy originating from lymphocytes. Although the disease can occur at all ages, common onset begins in adults over 40 years of age, with an incidence that increases with age. NHL is characterized by clonal proliferation of lymphocytes that accumulate in lymph nodes, blood, bone marrow, and spleen, but may involve any major organ. The current classification system used by pathologists and clinicians is the World Health Organization (WHO) tumor classification, which organizes NHL into precursor and mature B-cell or T-cell neoplasms. For entry into clinical trials, Physician's Data Query currently divides NHL into indolent or aggressive. The indolent NHL group mainly includes follicular subtypes, small lymphocytic lymphoma, mucosa-associated lymphoid tissue (MALT), and marginal zone; indolence covers approximately 50% of newly diagnosed B-cell NHL patients. Aggressive NHL includes patients histologically diagnosed with primary diffuse large B-cell cancer (DLBL, DLBCL, or DLCL; with 40% of all newly diagnosed patients having diffuse large cell), Burkitt lymphoma, and mantle cell lymphoma.

[0004] In addition to NHL, there are several types of leukemia that result from dysregulation of B cells.

[0005] Chronic lymphocytic leukemia (also called "chronic lymphoid leukemia" or "CLL") is a type of adult leukemia caused by an abnormal accumulation of B lymphocytes. In CLL, the malignant lymphocytes may appear normal and mature, but they cannot effectively respond to infections. CLL is the most common form of leukemia in adults. Men are twice as likely to develop CLL as women. However, the key risk factor is age. CLL is an incurable disease, but it progresses slowly in most cases. Many people with CLL live normal and active lives for many years. Due to its slow onset, early CLL is often not treated because it is believed that early CLL intervention will not improve survival time or quality of life. Instead, the disease is monitored over time. Initial CLL treatment varies depending on the exact diagnosis and progression of the disease. There are dozens of agents used for CLL therapy. Combination chemotherapy regimens such as FCR (fludarabine, cyclophosphamide, and rituximab) and BR (Ibrutinib and rituximab) are effective for both newly diagnosed and relapsed CLL. Allogeneic bone marrow (stem cell) transplantation is rarely used as a first-line treatment for CLL because of its risks.

[0006] Another type of leukemia is small lymphocytic lymphoma (SLL), which is considered a variant of CLL that lacks the clonal lymphocytosis required for CLL diagnosis, but otherwise shares pathological and immunophenotypic features (Campo et al., 2011). The definition of SLL requires the presence of lymphadenopathy and / or splenomegaly. In addition, the number of B lymphocytes in the peripheral blood should not exceed 5x10 9 / L. In SLL, the diagnosis should be confirmed by histopathological evaluation of lymph node biopsy whenever possible (Hallek et al., 2008).

[0007] Another type of leukemia, acute lymphoblastic leukemia, is characterized by the overproduction and continued proliferation of malignant and immature white blood cells (also called lymphoblasts) in the bone marrow. Acute lymphoblastic leukemia is most common in childhood, with a peak incidence at 4-5 years of age.

[0008] The human CD19 molecule is a structurally unique cell surface receptor expressed on the surface of human B cells, including but not limited to pre-B cells, early developing B cells (i.e., immature B cells), mature B cells through terminal differentiation to plasma cells, and malignant B cells. CD19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemias, hairy cell leukemias, common acute lymphocytic leukemias, and some Null-acute lymphoblastic leukemias (Nadler et al., J. Immunol., 131:244-250 (1983); Loken et al., Blood, 70:1316-1324 (1987); Uckun et al., Blood, 71:13-29 (1988); Anderson et al., 1984. Blood, 63:1424-1433 (1984); Scheuermann, Leuk. Lymphoma, 18:385-397 (1995)). The expression of CD19 on plasma cells further suggests that it may be expressed on differentiated B-cell tumors, such as multiple myeloma, plasmacytoma, Waldenstrom's tumor (Grossbard et al., Br. J. Haematol, 102: 509-15 (1998); Treon et al., Semin. Oncol, 30: 248-52 (2003)). Therefore, the CD19 antigen is a target for the treatment of various cancers with immunotherapy, such as non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and / or acute lymphoblastic leukemia, including each of the subtypes described herein.

[0009] Tafasitamab (formerly known as MOR208 and ) is a humanized monoclonal antibody targeting the antigen CD19. Dafacitinib has been engineered in the IgG Fc region to enhance antibody-dependent cell-mediated cytotoxicity (ADCC), thereby improving the key mechanism of tumor cell killing and providing the potential for enhanced efficacy compared to conventional antibodies, i.e., non-enhanced antibodies. Dafacitinib has been in or is currently being studied in several clinical trials, such as in CLL, ALL, and NHL. Based on the L-MIND trial, Dafacitinib received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2020 for combined treatment of adults with R / R DLBCL with lenalidomide. The recommended dose of Dafacitinib is 12 mg / kg, administered as an intravenous (iv) infusion.

[0010] Despite the recent discovery and development of several anti-cancer agents, due to the poor prognosis of many types of cancer, including CD19-expressing tumors, there remains a need for improved methods or therapeutics for treating these types of cancer. Summary of the invention

[0011] It is recognized that there is a need to optimize the darfaxomab dosing regimen to reduce the frequency of hospital / clinical visits for patients treated with darfaxomab. It is expected that reducing the overall frequency of clinic visits by half will reduce patient burden and support long-term treatment compliance. In addition, given the severity of the disease, reduced hospital visits may reduce exposure to nosocomial infections in a population that is already susceptible to the disease.

[0012] The present disclosure provides a treatment paradigm for a therapy comprising an anti-CD19 antibody, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg.

[0013] In one aspect, the present disclosure relates to an anti-CD 19 antibody for use in treating cancer, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg.

[0014] In one aspect, the disclosure relates to a method of treating cancer comprising administering an anti-CD 19 antibody to a human subject in need of such treatment, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg.

[0015] In one aspect, the disclosure relates to an anti-CD19 antibody for use in treating cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week to at least once every two weeks. In one embodiment, the dosing frequency is reduced to once every two weeks. In one embodiment, the dosing frequency is reduced to once every 4 weeks. In one embodiment, the dosing frequency is reduced to once every 5 weeks. In one embodiment, the dosing frequency is reduced to once every 6 weeks. In one embodiment, the dosing frequency is reduced to once every 7 weeks. In one embodiment, the dosing frequency is reduced to once every 8 weeks.

[0016] In one aspect, the disclosure relates to an anti-CD 19 antibody for use in treating cancer, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week to once every 4 weeks.

[0017] In one aspect, the disclosure relates to an anti-CD19 antibody for use in treating cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week to once every two weeks and to once every 4 weeks.

[0018] In one aspect, the present disclosure relates to an anti-CD19 antibody for use in treating cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week (QW) to once every two weeks (Q2W) starting on Cycle 1 Day 15 (C1D15), and from Q2W to once every 4 weeks (Q4W) starting on Cycle 4 Day 1.

[0019] In one aspect, the present disclosure relates to an anti-CD 19 antibody for use in treating cancer, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing regimen by 20%, 30%, 40%, 50%, 60%, 70% or more infusions compared to administering the anti-CD 19 antibody at a dose of 12 mg / kg.

[0020] In one aspect, the disclosure relates to a method of reducing the dosing frequency of an anti-CD 19 antibody in the treatment of cancer, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg.

[0021] In one aspect, the disclosure relates to a method for reducing the frequency of administration of an anti-CD19 antibody in the treatment of cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the frequency of administration from once a week to at least once every two weeks. In one embodiment, the frequency of administration is reduced to once every 2 weeks. In one embodiment, the frequency of administration is reduced to once every 4 weeks. In one embodiment, the frequency of administration is reduced to once every 5 weeks. In one embodiment, the frequency of administration is reduced to once every 6 weeks. In one embodiment, the frequency of administration is reduced to once every 7 weeks. In one embodiment, the frequency of administration is reduced to once every 8 weeks.

[0022] In one aspect, the disclosure relates to a method of reducing the dosing frequency of an anti-CD19 antibody in the treatment of cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week to once every 4 weeks.

[0023] In one aspect, the disclosure relates to a method of reducing the dosing frequency of an anti-CD 19 antibody in the treatment of cancer, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week to once every two weeks and to once every 4 weeks.

[0024] In one aspect, the disclosure relates to a method of reducing the dosing frequency of an anti-CD19 antibody in the treatment of cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose reduces the dosing frequency from once a week (QW) to once every two weeks (Q2W) starting on Cycle 1 Day 15 (C1D15), and from Q2W to once every 4 weeks (Q4W) starting on Cycle 4 Day 1.

[0025] In one aspect, the present disclosure relates to a method of reducing the dosing frequency of an anti-CD 19 antibody in the treatment of cancer, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg, and wherein this dose results in a dosing regimen that reduces infusions by 20%, 30%, 40%, 50%, 60%, 70% or more compared to administering the anti-CD 19 antibody at a dose of 12 mg / kg.

[0026] In one aspect, the disclosure relates to methods for reducing the adverse effects of an anti-CD19 antibody for treating cancer at a dosage of at least 24 mg / kg, wherein the anti-CD19 antibody is administered at a dosage of 12 mg / kg before increasing to a dosage of at least 24 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dosage of 12 mg / kg for the first, second, or third administrations, and wherein the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg after the first, second, or third administrations. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dosage of at least 24 mg / kg.

[0027] In one aspect, the present disclosure relates to a method of reducing adverse effects of an anti-CD19 antibody used to treat cancer at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose of at least 24 mg / kg from day 15. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of at least 24 mg / kg.

[0028] In some embodiments, the anti-CD19 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising a HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), a HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), and a HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), and the light chain variable region comprising a LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), a LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and a LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).

[0029] In some embodiments, the anti-CD19 antibody comprises a heavy chain variable region comprising a HCDR1 region of SYVMH (SEQ ID NO: 1), a HCDR2 region of NPYNDG (SEQ ID NO: 2), and a HCDR3 region of GTYYYGTRVFDY (SEQ ID NO: 3), and the light chain variable region comprises a LCDR1 region of RSSKSLQNVNGNTYLY (SEQ ID NO: 4), a LCDR2 region of RMSNLNS (SEQ ID NO: 5), and a LCDR3 region of MQHLEYPIT (SEQ ID NO: 6).

[0030] In some embodiments, the anti-CD 19 antibody comprises a heavy chain variable region of EVQLVESGGGLVK PGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDG TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (SEQ ID NO:7) and a light chain variable region of DIV MTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:8).

[0031] In some embodiments, the anti-CD19 antibody has effector function. On the other hand, the antibody or antibody fragment having specificity for CD19 has enhanced effector function. In one embodiment, the effector function is ADCC. In one embodiment, the antibody or antibody fragment having specificity for CD19 has enhanced ADCC activity. In another embodiment, the antibody or antibody fragment having specificity for CD19 comprises an Fc domain, and the Fc domain comprises amino acid substitutions at positions S239 and / or I332, wherein numbering is according to the EU index as in Kabat. In another embodiment, the antibody or antibody fragment having specificity for CD19 comprises an Fc domain, and the Fc domain comprises an S239D amino acid substitution and an I332E amino acid substitution, wherein numbering is according to the EU index as in Kabat.

[0032] In some embodiments, the anti-CD 19 antibody comprises a heavy chain constant region of ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 9).

[0033] In some embodiments, the anti-CD 19 antibody comprises a light chain constant region of RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 10).

[0034] In some embodiments, the anti-CD19 antibody comprises a heavy chain constant region of ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 9) and RTVAAPSVFIFPPSDEQLKSGT The light chain constant region of ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 10).

[0035] In some embodiments, the anti-CD 19 antibody comprises EVQLVESGGGLVK PGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTK GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID The heavy chain region of NO:11) and DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAG TKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ The light chain region of ID NO:12).

[0036] In some embodiments, the anti-CD19 antibody is dafacitinib.

[0037] In some embodiments, the anti-CD 19 antibody is administered intravenously.

[0038] In some embodiments, the anti-CD19 antibody is administered by intravenous infusion.

[0039] In some embodiments, the anti-CD19 antibody is administered by subcutaneous injection.

[0040] In some embodiments, the anti-CD19 antibody is administered subcutaneously.

[0041] In some embodiments, the cancer is a CD19-positive cancer.

[0042] In some embodiments, the cancer is a hematological malignancy.

[0043] In some embodiments, the cancer is lymphoma or leukemia.

[0044] In some embodiments, the cancer is chronic lymphocytic leukemia or non-Hodgkin's lymphoma.

[0045] In some embodiments, the cancer is CD19-positive chronic lymphocytic leukemia or CD19-positive non-Hodgkin's lymphoma.

[0046] In some embodiments, the cancer is non-Hodgkin's lymphoma. In some embodiments, the human subject suffers from relapsed or refractory non-Hodgkin's lymphoma. In some embodiments, the human subject suffers from relapsed or refractory CD19 positive aggressive non-Hodgkin's lymphoma. In some embodiments, the human subject suffers from relapsed or refractory CD19 positive aggressive non-Hodgkin's lymphoma and progresses under at least one previous treatment regimen. In some embodiments, the cancer is follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) or Burkitt's lymphoma. In some embodiments, the human subject suffers from relapsed or refractory diffuse large B-cell lymphoma (r / r DLBCL).

[0047] In some embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion. In some embodiments, the intravenous infusion is administered over at least 1.5 hours, at least 2 hours, at least 2.5 hours, at least 3 hours, at least 3.5 hours, at least 4 hours, or at least 4.5 hours.

[0048] In some other embodiments, the intravenous infusion is administered within at least 1.5 to 2.5 hours, at least 2.5 to 3 hours, at least 2.5 to 3.5 hours, at least 3 to 4 hours or at least 3.5 to 4.5 hours. In some other embodiments, the intravenous infusion is administered within 1.5 to 2.5 hours, 2 hours, 2.5 to 3 hours, 3 hours, 2.5 to 3.5 hours, 3 to 4 hours or 3.5 to 4.5 hours. In some other embodiments, the intravenous infusion is administered with an infusion rate of at least 30 mL / h, at least 40 mL / h, at least 50 mL / h, at least 60 mL / h or at least 70 mL / h. In some other embodiments, the intravenous infusion is initially administered with an infusion rate of 30 mL / h, 40 mL / h, 50 mL / h, 60 mL / h or 70 mL / h for the first 30 minutes and then increased.

[0049] In some embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2.5 hours. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2 hours. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 2 hours.

[0050] In some embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4.5 hours. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4 hours. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4 hours. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4.5 hours. In some other embodiments, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD 19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered over 4 hours.

[0051] In some embodiments, the disclosure relates to a method for treating a cancer in a human subject in need thereof, the method comprising administering an anti-CD19 antibody to the human subject, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg before increasing to a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg). In some embodiments, for the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of 12 mg / kg, and wherein after the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg). In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of at least 24 mg / kg.

[0052] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, comprising administering an anti-CD19 antibody to the human subject, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose of at least 24 mg / kg from day 15. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of at least 24 mg / kg.

[0053] In some embodiments, the disclosure relates to a method for treating cancer in a human subject in need thereof, the method comprising administering an anti-CD19 antibody to the human subject, wherein the anti-CD19 antibody is administered as an intravenous infusion within 1.5 to 2.5 hours at a dose of 12 mg / kg before increasing to a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), and wherein the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3 to 4.5 hours. In some other embodiments, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3 to 4 hours. In some other embodiments, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3.5 to 4 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3.5 to 4.5 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 4 hours.

[0054] In some embodiments, for the first, second or third administration, the anti-CD19 antibody is administered as an intravenous infusion within 1.5 to 2.5 hours at a dosage of 12 mg / kg, and wherein after the first, second or third administration, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), and wherein the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3 to 4.5 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3 to 4 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3.5 to 4 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 3.5 to 4.5 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 4 hours. In some embodiments, the anti-CD19 antibody is administered weekly, biweekly, or once every four weeks at least at a dosage of 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg).

[0055] In some embodiments, the disclosure relates to a method for treating a cancer in a human subject in need thereof, the method comprising administering an anti-CD19 antibody to the human subject, wherein the anti-CD19 antibody is administered as an intravenous infusion within 1.5 to 2.5 hours at a dose of 12 mg / kg before increasing to a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), and wherein the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 1.5 to 2.5 hours. In some other embodiments, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 1.5 to 2 hours. In some other embodiments, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 2 hours. In some other embodiments, the increasing dose of at least 24 mg / kg (eg, 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion over 2 hours.

[0056] In some embodiments, for the first, second or third administration, the anti-CD19 antibody is administered as an intravenous infusion within 1.5 to 2.5 hours at a dosage of 12 mg / kg, and wherein after the first, second or third administration, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), and wherein the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 1.5 to 2.5 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 1.5 to 2 hours. In some other embodiments, the increased dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion within 2 hours.

[0057] In some embodiments, for the first, second, and third administrations, the anti-CD 19 antibody is administered at a dose of 12 mg / kg as an intravenous infusion over 1.5 to 2.5 hours, and wherein following the first, second, and third administrations, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), and wherein for the first, second, and third administrations, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion over 3 to 4.5 hours, and wherein for all subsequent administrations, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion over 1.5 to 2 hours.

[0058] In some embodiments, for the first, second, and third administrations, the anti-CD 19 antibody is administered at a dose of 12 mg / kg as an intravenous infusion over 2 hours, and wherein following the first, second, and third administrations, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), and wherein for the first, second, and third administrations, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion over 4 hours, and wherein for all subsequent administrations, the increased dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) is administered as an intravenous infusion over 2 hours.

[0059] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0060] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody is administered at a dose of 12 mg / kg within 1.5 to 2.5 hours;

[0061] On day 15 of the first 28-day treatment cycle and on days 1 and 15 of the second and any subsequent 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and within 3 to 4.5 hours.

[0062] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0063] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody is administered at a dose of 12 mg / kg within 1.5 to 2.5 hours;

[0064] On day 15 of the first 28-day treatment cycle and on days 1 and 15 of the second and any subsequent 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and within 4 hours.

[0065] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0066] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody is administered at a dose of 12 mg / kg within 1.5 to 2.5 hours;

[0067] On day 15 of the first 28-day treatment cycle and on days 1 and 15 of the second and any subsequent 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and within 1.5 to 2.5 hours.

[0068] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0069] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody is administered at a dose of 12 mg / kg within 1.5 to 2.5 hours;

[0070] On day 15 of the first 28-day treatment cycle and on days 1 and 15 of the second and any subsequent 28-day treatment cycles, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and within 2 to 2.5 hours or within 3 hours.

[0071] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0072] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody is administered at a dose of 12 mg / kg within 1.5 to 2.5 hours;

[0073] On day 15 of the first 28-day treatment cycle and on days 1 and 15 of the second and any subsequent 28-day treatment cycles, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and within 2 hours.

[0074] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0075] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody was administered at a dose of 12 mg / kg within 2 hours;

[0076] On Day 15 of the first 28-day treatment cycle and Days 1 and 15 of the second and third 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and is administered within 4 hours, and on Day 1 of the fourth 28-day treatment cycle and Day 1 of any subsequent 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and is administered within 2 hours.

[0077] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0078] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody is administered at a dose of 12 mg / kg within 1.5 to 2.5 hours;

[0079] On Day 15 of the first 28-day treatment cycle and Days 1 and 15 of the second and third 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and is administered within 3 to 4.5 hours, and on Day 1 of the fourth 28-day treatment cycle and Day 1 of any subsequent 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and is administered within 1.5 to 2 hours.

[0080] In some embodiments, the present disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD19 antibody, wherein the anti-CD19 antibody is administered as an intravenous infusion according to the following schedule:

[0081] On days 1, 4, and 8 of the first 28-day treatment cycle, the anti-CD19 antibody was administered at a dose of 12 mg / kg within 2 hours;

[0082] On Day 15 of the first 28-day treatment cycle and Days 1 and 15 of the second and third 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and is administered within 4 hours, and on Day 1 of the fourth 28-day treatment cycle and Day 1 of any subsequent 28-day treatment cycles, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and is administered within 2 hours.

[0083] In some embodiments, the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) and in the form of an intravenous infusion over 4 hours from day 15. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose ranging from 24 mg / kg to 30 mg / kg.

[0084] In some embodiments, the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered as an intravenous infusion in a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg) from day 15 and within 1.5 to 2.5 hours, within 1.5 to 2 hours, within 2 hours, within 2 to 2.5 hours, within 2 to 3 hours, or within 3 hours. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose ranging from 24 mg / kg to 30 mg / kg.

[0085] In some embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2.5 hours, and wherein the intravenous infusion is administered at an infusion rate of 70 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2 hours, and wherein the intravenous infusion is administered at an infusion rate of 70 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 2 hours, and wherein the intravenous infusion is administered at an infusion rate of 70 mL / h for 30 minutes before the intravenous infusion.

[0086] In some embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4.5 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4.5 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 4 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes.

[0087] In some embodiments, the anti-CD19 antibody is administered with multiple administrations, the multiple administrations comprising the first administration of a dosage of at least 24 mg / kg and one or more subsequent administrations, each of the first administration of the anti-CD19 antibody and one or more subsequent administrations is administered in the form of intravenous infusion, and wherein the first intravenous infusion is administered at an infusion rate of 70 mL / h for the first 30 minutes within 1.5 to 2.5 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of 70 mL / h for the first 30 minutes within 1.5 to 2 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of 70 mL / h for the first 30 minutes within 2 hours. In some embodiments, one or more subsequent intravenous infusions are administered within 1.5 to 2.5 hours, within 1.5 to 2 hours, or within 2 hours. In other embodiments, the anti-CD 19 antibody is administered in multiple administrations comprising a first administration and one or more subsequent administrations at a dose of at least 24 mg / kg, wherein each of the first administration and one or more subsequent administrations of the anti-CD 19 antibody is administered as an intravenous infusion, and wherein the first intravenous infusion is administered at an infusion rate of 70 mL / h in the first 30 minutes over 1.5 to 2.5 hours, and the one or more subsequent intravenous infusions are administered over 1.5 to 2 hours or over 2 hours.

[0088] In some embodiments, the anti-CD19 antibody is administered with multiple administrations, the multiple administrations comprising the first administration of a dosage of at least 24 mg / kg and one or more subsequent administrations, wherein each of the first administration of the anti-CD19 antibody and one or more subsequent administrations is administered in the form of intravenous infusion, and wherein the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3 to 4.5 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3 to 4 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3.5 to 4 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3.5 to 4.5 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 4 hours. In some embodiments, one or more subsequent intravenous infusions are administered within 3 to 4.5 hours, within 3 to 4 hours, within 3.5 to 4 hours, within 3.5 to 4.5 hours, or within 4 hours.

[0089] In some embodiments, the anti-CD19 antibody is administered at a dosage of 24 mg / kg or 30 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2.5 hours. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2 hours. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 2 hours.

[0090] In some embodiments, the anti-CD19 antibody is administered at a dosage of 24 mg / kg or 30 mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4.5 hours. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4 hours. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4 hours. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4.5 hours. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 4 hours.

[0091] In some embodiments, the anti-CD19 antibody is administered at a dosage of 24mg / kg or 30mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2.5 hours, and wherein the intravenous infusion is administered at an infusion rate of 70mL / h for the first 30 minutes. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24mg / kg (e.g., 24mg / kg or 30mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 1.5 to 2 hours, and wherein the intravenous infusion is administered at an infusion rate of 70mL / h for the first 30 minutes. In some other embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered over 2 hours, and wherein the intravenous infusion is administered at an infusion rate of 70 mL / h for the first 30 minutes.

[0092] In some embodiments, the anti-CD19 antibody is administered at a dosage of 24mg / kg or 30mg / kg, wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4.5 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30mL / h for the first 30 minutes. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24mg / kg (e.g., 24mg / kg or 30mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3 to 4 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30mL / h for the first 30 minutes. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered within 3.5 to 4.5 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for 30 minutes before the intravenous infusion. In some other embodiments, the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg (e.g., 24 mg / kg or 30 mg / kg), wherein the anti-CD 19 antibody is administered as an intravenous infusion, and wherein the intravenous infusion is administered over 4 hours, and wherein the intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes.

[0093] In some embodiments, the anti-CD19 antibody is administered with multiple administrations, and the multiple administrations include at least 24 mg / kg, for example, the first administration of a dosage of 24 mg / kg or 30 mg / kg and one or more subsequent administrations, wherein the first administration of the anti-CD19 antibody and one or more subsequent administrations are each administered in the form of intravenous infusion, and wherein the first intravenous infusion is administered within 1.5 to 2.5 hours, with an infusion rate of 70 mL / h for the first 30 minutes. In some other embodiments, the first intravenous infusion is administered within 1.5 to 2 hours, with an infusion rate of 70 mL / h for the first 30 minutes. In some other embodiments, the first intravenous infusion is administered within 2 hours, with an infusion rate of 70 mL / h for the first 30 minutes. In some embodiments, one or more subsequent intravenous infusions are administered within 1.5 to 2.5 hours, within 1.5 to 2 hours, or within 2 hours. In other embodiments, the anti-CD 19 antibody is administered in multiple administrations comprising a first administration and one or more subsequent administrations at a dose of at least 24 mg / kg, e.g., 24 mg / kg or 30 mg / kg, wherein the first administration and one or more subsequent administrations of the anti-CD 19 antibody are each administered as an intravenous infusion, and wherein the first intravenous infusion is administered over 1.5 to 2.5 hours with an infusion rate of 70 mL / h for the first 30 minutes, and the one or more subsequent intravenous infusions are administered over 1.5 to 2 hours or over 2 hours.

[0094] In some embodiments, the anti-CD19 antibody is administered with multiple administrations, and the multiple administrations include at least 24 mg / kg, for example, the first administration of a dosage of 24 mg / kg or 30 mg / kg and one or more subsequent administrations, wherein each of the first administration of the anti-CD19 antibody and one or more subsequent administrations is administered in the form of intravenous infusion, and wherein the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3 to 4.5 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3 to 4 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3.5 to 4 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 3.5 to 4.5 hours. In some other embodiments, the first intravenous infusion is administered at an infusion rate of at least 30 mL / h for the first 30 minutes within 4 hours. In some embodiments, one or more subsequent intravenous infusions are administered within 3 to 4.5 hours, within 3 to 4 hours, within 3.5 to 4 hours, within 3.5 to 4.5 hours, or within 4 hours.

[0095] In some embodiments, the anti-CD 19 antibody is administered on day 1 of a treatment cycle. In some embodiments, the treatment cycle is 28 days.

[0096] In some embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dosage of at least 24 mg / kg once a week, once every two weeks, or once every four weeks.

[0097] In some embodiments, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg before increasing to a dose of at least 24 mg / kg. In some embodiments, for the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of 12 mg / kg, and wherein after the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of at least 24 mg / kg. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of at least 24 mg / kg.

[0098] In some embodiments, the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose of at least 24 mg / kg from day 15. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of at least 24 mg / kg.

[0099] In some embodiments, the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on Day 1, Day 4, and Day 9 of the first cycle, and a dose of at least 24 mg / kg is administered on Day 15 of the first cycle; b) a dose of at least 24 mg / kg is administered on Day 1 and Day 15 of Cycles 2-3; and c) a dose of at least 24 mg / kg is administered on Day 1 of other subsequent cycles.

[0100] In some embodiments, the anti-CD19 antibody is administered at a dosage in the range of 24 mg / kg to 30 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dosage in the range of 24 mg / kg to 30 mg / kg. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dosage in the range of 24 mg / kg to 30 mg / kg.

[0101] In some embodiments, the anti-CD19 antibody is administered at a dosage within the range of 24 mg / kg to 30 mg / kg, wherein the anti-CD19 antibody is administered at a dosage of 12 mg / kg before increasing to a dosage within the range of 24 mg / kg to 30 mg / kg. In some embodiments, for the previous one, two or three administrations, the anti-CD19 antibody is administered at a dosage of 12 mg / kg, and wherein after the previous one, two or three administrations, the anti-CD19 antibody is administered at a dosage within the range of 24 mg / kg to 30 mg / kg. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dosage within the range of 24 mg / kg to 30 mg / kg.

[0102] In some embodiments, the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose ranging from 24 mg / kg to 30 mg / kg from day 15. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose ranging from 24 mg / kg to 30 mg / kg.

[0103] In some embodiments, the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on Day 1, Day 4, and Day 9 of the first cycle, and a dose ranging from 24 mg / kg to 30 mg / kg is administered on Day 15 of the first cycle; b) a dose ranging from 24 mg / kg to 30 mg / kg is administered on Day 1 and Day 15 of Cycles 2-3; and c) a dose ranging from 24 mg / kg to 30 mg / kg is administered on Day 1 of other subsequent cycles.

[0104] In some embodiments, the anti-CD19 antibody is administered at a dose of 24 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dose of 24 mg / kg once every two weeks.

[0105] In some embodiments, the anti-CD19 antibody is administered at a dose of 24 mg / kg, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg before increasing to a dose of 24 mg / kg. In some embodiments, for the previous one, two or three administrations, the anti-CD19 antibody is administered at a dose of 12 mg / kg, and wherein after the previous one, two or three administrations, the anti-CD19 antibody is administered at a dose of 24 mg / kg. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of 24 mg / kg.

[0106] In some embodiments, the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose of 24 mg / kg from day 15. In some embodiments, the anti-CD19 antibody is administered once a week, once every two weeks, or once every four weeks at a dose of 24 mg / kg.

[0107] In some embodiments, the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on days 1, 4, and 9 of the first cycle, and a dose of 24 mg / kg is administered on day 15 of the first cycle; b) a dose of 24 mg / kg is administered on days 1 and 15 of cycles 2-3; and c) a dose of 24 mg / kg is administered on day 1 of other subsequent cycles.

[0108] In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg once every two weeks.

[0109] In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg before increasing to a dose of 30 mg / kg. In some embodiments, for the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of 12 mg / kg, and wherein after the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of 30 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg once a week, once every two weeks, or once every four weeks.

[0110] In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg, wherein the anti-CD19 antibody is administered at a dose of 12 mg / kg before increasing to a dose of 24 mg / kg and before increasing to a dose of 30 mg / kg. In some embodiments, for the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of 12 mg / kg, and wherein after the first, second, or third administrations, the anti-CD19 antibody is administered at a dose of 24 mg / kg, and wherein after the administration at a dose of 24 mg / kg, the anti-CD19 antibody is administered at a dose of 30 mg / kg. In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg once a week, once every two weeks, or once every four weeks.

[0111] In some embodiments, the anti-CD19 antibody is administered at a dose of 12 mg / kg on day 1, day 4, and day 8 from the start of treatment, and the anti-CD19 antibody is administered at a dose of 30 mg / kg from day 15. In some embodiments, the anti-CD19 antibody is administered at a dose of 30 mg / kg once a week, once every two weeks, or once every four weeks.

[0112] In some embodiments, the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on day 1, day 4, and day 9 of the first cycle, and a dose of 30 mg / kg is administered on day 15 of the first cycle; b) a dose of 30 mg / kg is administered on day 1 and day 15 of cycles 2-3; and c) a dose of 30 mg / kg is administered on day 1 of other subsequent cycles.

[0113] In some embodiments, the anti-CD19 antibody is administered in combination with lenalidomide. In some aspects, lenalidomide is administered orally. In some aspects, lenalidomide is administered daily from the 1st day to the 21st day of a repeated 28-day cycle. In some aspects, lenalidomide is administered daily from the 1st day to the 21st day of up to 12 repeated 28-day cycles. In some aspects, the dosage of lenalidomide is at least 20 mg per day. In some aspects, the dosage of lenalidomide is 25 mg per day.

[0114] In some embodiments, the anti-CD19 antibody is administered in combination with lenalidomide, wherein lenalidomide is administered orally at a dose of 25 mg on day 1 to day 21 of repeated 28-day cycles. In some embodiments, the anti-CD19 antibody is administered in combination with lenalidomide, wherein lenalidomide is administered orally at a dose of 25 mg and daily on day 1 to day 21 of 12 repeated 28-day cycles. BRIEF DESCRIPTION OF THE DRAWINGS

[0115] Figure 1 and Figure 2 : Box plots of model-predicted PK parameters based on 2000 randomly generated patients dosed according to the L-MIND, 12 / 24 mg / kg (Cohort 1) and 12 / 30 mg / kg (Cohort 2) dosing regimens.

[0116] Figure 3 : Overlay of model-predicted medians of dafacitinib concentration-time profiles administered according to L MIND and 12 / 30 mg / kg dosing regimens. DETAILED DESCRIPTION

[0117] The term "CD19" refers to a protein called CD19, which has the following synonyms: B4, B lymphocyte antigen CD19, B lymphocyte surface antigen B4, CVID3, differentiation antigen CD19, MGC12802, and T cell surface antigen Leu-12. The term also encompasses naturally occurring CD19 variants, such as splice variants, allelic variants, and isoforms.

[0118] In one embodiment, the amino acid sequence of human CD19 is:

[0119]

[0120] According to Table A, "MOR208" and "XmAb 5574" and "Darfaxine" are used as synonyms for anti-CD19 antibodies. Table A provides the amino acid sequence of MOR208 / Darfaxine. The MOR208 antibody is described in U.S. Pat. No. 8,524,867, which is incorporated herein by reference in its entirety (in U.S. Pat. No. 8,524,867, the complete heavy chain of MOR208 is SEQ ID NO: 87 and the complete light chain of MOR208 is SEQ ID NO: 106).

[0121] "Fc region" means the constant region of an antibody, which in humans may belong to the IgG1, 2, 3, 4 subclass or others. The sequence of the human Fc region is available on the IMGT website.

[0122] The term "antibody" means an immunoglobulin molecule that recognizes and specifically binds to a target such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the above substances via at least one antigen recognition site in the variable region of the immunoglobulin molecule. As used herein, the term "antibody" encompasses polyclonal antibodies, monoclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) mutants, multispecific antibodies (e.g., bispecific antibodies produced by, for example, at least two complete antibodies), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising the antigenic determinant of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site. Antibodies may have any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), categories (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclasses. Both light and heavy chains are divided into structural and functional homologous regions. The different classes of immunoglobulins have different and well-known subunit structures and three-dimensional configurations.The antibodies may be naked or conjugated directly or via one or more linkers to other molecules, such as toxins, radioisotopes, etc.

[0123] The term "anti-CD19 antibody" or "antibody that binds to CD19" refers to an antibody that is capable of binding CD19 with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD19.

[0124] "Monoclonal antibody" refers to a homogeneous or substantially homogeneous antibody population that is involved in highly specific recognition and binding to a single antigenic determinant or epitope. This is in contrast to polyclonal antibodies, which typically include different antibodies against different antigenic determinants. The term "monoclonal antibody" encompasses complete and full-length monoclonal antibodies as well as antibody fragments (e.g., Fab, Fab', F(ab')2, Fv), single-chain (scFv) mutants, fusion proteins comprising antibody portions, and any other modified immunoglobulin molecules comprising an antigen recognition site. In addition, "monoclonal antibody" refers to such antibodies produced in a variety of ways including, but not limited to, hybridomas, phage selection, recombinant expression, and transgenic animals.

[0125] The term "chimeric antibody" refers to an antibody in which the amino acid sequence of the immunoglobulin molecule is derived from two or more species. Typically, the variable regions of the light and heavy chains correspond to the variable regions of antibodies derived from one mammalian species (e.g., mouse, rat, rabbit, etc.) with the desired specificity, affinity, and capacity, while the constant regions are homologous to sequences in antibodies derived from another species (usually humans) to avoid eliciting an immune response in the species.

[0126] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or combination of one or more compounds that, when administered (sequentially or simultaneously), elicits a desired biological or medicinal response, e.g., destroying, slowing or suppressing the growth of target cancer cells, slowing or suppressing the progression of cancer in a patient, and / or delaying, eliminating, reducing or otherwise ameliorating one or more symptoms of cancer in a patient. The therapeutically effective amount may vary depending on the intended application or the patient and disease condition being treated, and may depend on factors such as: the patient's weight and age, the severity of the disease condition, the mode of administration, etc., which can be readily determined by one skilled in the art. The term "effective amount" or "therapeutically effective amount" also applies to an amount, such as one or more doses, that will induce a particular response in a target cell, such as a reduction in platelet adhesion and / or cell migration.

[0127] "Administered" or "administration" includes, but is not limited to, delivery by an injectable form, such as intravenous, intramuscular, intradermal or subcutaneous routes, or by a mucosal route, such as as a nasal spray or aerosol for inhalation, or as an ingestible solution, capsule or tablet.

[0128] Anti-CD19 antibodies

[0129] CD19 is widely and homogenously expressed in different B-cell derived hematological cancers. CD19 is able to enhance B-cell receptor signaling, which is important for B-cell survival and is therefore a therapeutic target for drugs aimed at treating B-cell related lymphomas and leukemias.

[0130] Antibodies, such as dafacitinib, can be made, for example, by preparing and expressing a synthetic gene encoding the amino acid sequence or by mutating a human germline gene to provide a gene encoding the amino acid sequence. In addition, this antibody and other anti-CD19 antibodies can be obtained, for example, using one or more of the following methods.

[0131] Humanized antibodies can be produced by replacing sequences of Fv variable regions that are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for producing humanized antibodies are provided by Morrison, SL, Science, 229: 1202-1207 (1985); Oi et al., BioTechniques, 4: 214 (1986), and US 5,585,089; US 5,693,761; US ​​5,693,762; US 5,859,205; and US 6,407,213. These methods include separating, manipulating and expressing nucleic acid sequences encoding all or part of the immunoglobulin Fv variable region from at least one of the heavy chain or light chain. The source of such nucleic acids is well known to those skilled in the art, and can be obtained, for example, from hybridomas, germline immunoglobulin genes or synthetic constructs that produce antibodies to a predetermined target as described above. The recombinant DNA encoding the humanized antibody can then be cloned into an appropriate expression vector.

[0132] Human germline sequences are disclosed, for example, in Tomlinson, IA et al., J. Mol. Biol., 227:776-798 (1992); Cook, GP et al., Immunol. Today, 16:237-42 (1995); Chothia, D. et al., J. Mol. Biol. 227:799-817 (1992); and Tomlinson et al., EMBO J., 14:4628-4638 (1995). The VBASE directory provides a comprehensive directory of human immunoglobulin variable region sequences (Tomlinson, IA et al., MRC Centre for Protein Engineering, Cambridge, UK compilation). These sequences can be used as a source of human sequences, for example for framework regions and CDRs. Consensus human framework regions can also be used, such as described in U.S. Pat. No. 6,300,064. Other methods of humanizing antibodies can also be used. For example, other methods can take into account the three-dimensional structure of the antibody, the framework position and immunogenic peptide sequence that are three-dimensionally close to the binding determinant. See, for example, WO 90 / 07861; U.S. Patent Nos. 5,693,762; 5,693,761; 5,585,089; 5,530,101; and 6,407,213; Tempest et al., (1991) Biotechnology 9:266-271. Another method is called "humaneering" and is described, for example, in US2005-008625.

[0133] The antibody may include a human Fc region, such as a wild-type Fc region or an Fc region including one or more changes. In one embodiment, the constant region is changed, such as a human IgG1 constant region mutated to include S239D and / or I332E substitutions. The antibody may also have a mutation that stabilizes the disulfide bond between the two heavy chains of the immunoglobulin, such as a mutation in the hinge region of IgG4, as disclosed in the art (e.g., Angal et al., (1993) Mol. Immunol. 30: 105-08). See also, for example, US2005-0037000. The anti-CD19 antibody may be in the form of a full-length antibody, or in the form of a low molecular weight anti-CD19 antibody (e.g., a biologically active antibody fragment or mini antibody), such as Fab, Fab', F(ab')2, Fv, Fd, dAb, scFv, and sc(Fv)2. Other anti-CD19 antibodies encompassed by the present disclosure include single domain antibodies (sdAb) containing a single variable chain such as VH or VL or biologically active fragments thereof. See, for example, Moller et al., J. Biol. Chem., 285(49):38348-38361 (2010); Harmsen et al., Appl. Microbiol. Biotechnol., 77(1):13-22 (2007); US2005 / 0079574 and Davies et al., (1996) Protein Eng., 9(6):531-7. Like intact antibodies, sdAbs are able to selectively bind to specific antigens. With a molecular weight of only 12-15 kDa, sdAbs are much smaller than common antibodies and even smaller than Fab fragments and single-chain variable fragments.

[0134] Provided herein are compositions comprising a mixture of an anti-CD19 antibody or its antigen-binding fragment and one or more of its acidic variants, for example, wherein the amount of the acidic variant is less than about 80%, 70%, 60%, 60%, 50%, 40%, 30%, 20%, 30%, 30%, 10%, 5% or 1%. Also provided are compositions comprising an anti-CD19 antibody or its antigen-binding fragment containing at least one deamidation site, wherein the pH of the composition is about 5.0 to about 6.5, such that, for example, at least about 90% of the anti-CD19 antibodies are not deamidated (i.e., less than about 10% of the antibody deamidates). In certain embodiments, less than about 5%, 3%, 2% or 1% of the antibody deamidates. The pH may be 5.0 to 6.0, for example 5.5 or 6.0. In certain embodiments, the pH of the composition is 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4 or 6.5.

[0135] An "acidic variant" is a variant of a polypeptide of interest that is more acidic than the polypeptide of interest (eg, as determined by cation exchange chromatography). An example of an acidic variant is a deamidated variant.

[0136] A "deamidated" variant of a polypeptide molecule is one in which one or more asparagine residues of the original polypeptide have been converted to aspartic acid, ie, the neutral amide side chain has been converted to a residue having an overall acidic character.

[0137] The term "mixture" as used herein for compositions comprising anti-CD19 antibodies or antigen-binding fragments thereof means the presence of the desired anti-CD19 antibodies or antigen-binding fragments thereof and one or more acidic variants thereof. The acidic variants may comprise primarily deamidated anti-CD19 antibodies with minor amounts of other acidic variants.

[0138] In certain embodiments, the binding affinity (KD), association rate (KD associat) and / or dissociation rate (KD dissociat) of an antibody mutated to eliminate deamidation is similar to the binding affinity of the wild-type antibody, e.g., the difference is less than about 5-fold, 2-fold, 1-fold (100%), 50%, 30%, 20%, 10%, 5%, 3%, 2% or 1%.

[0139] Bispecific Antibodies

[0140] In certain embodiments, the anti-CD19 antibodies or antigen-binding fragments thereof described herein are present in bispecific antibodies. Exemplary bispecific antibodies can bind to two different epitopes of CD19 protein. Other such antibodies can combine the CD19 binding site with a binding site for another protein. Bispecific antibodies can be prepared as full-length antibodies or their low molecular weight forms (e.g., F(ab')2 bispecific antibodies, sc(Fv)2 bispecific antibodies, bifunctional antibody bispecific antibodies).

[0141] The traditional production of full-length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain light chain pairs, where the two chains have different specificities (Millstein et al., Nature, 305: 537-539 (1983)). In different methods, the antibody variable domains with the desired binding specificity are fused to the immunoglobulin constant domain sequences. The DNA encoding the immunoglobulin heavy chain fusion and (if necessary) the immunoglobulin light chain are inserted into separate expression vectors and co-transfected into suitable host cells. This provides greater flexibility in adjusting the ratio of the three polypeptide fragments. However, when the expression of at least two polypeptide chains in equal ratios produces a high yield, it is possible to insert the coding sequences of two or all three polypeptide chains into a single expression vector.

[0142] According to another method described in U.S. Patent No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers recovered from recombinant cell culture. Preferably, the interface comprises at least a portion of the CH3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced by larger side chains (e.g., tyrosine or tryptophan). On the interface of the second antibody molecule, a compensatory "cavity (cavities)" with the same or similar size as the large side chain is produced by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). This provides a mechanism to increase the heterodimer yield and exceed other undesirable final products such as homodimers.

[0143] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin and the other antibody to biotin. Heteroconjugate antibodies can be made using any suitable cross-linking method.

[0144] "Diabody" technology provides an alternative mechanism for making bispecific antibody fragments. The fragments comprise a VH connected to a VL via a linker that is too short to allow pairing between the two domains on the same chain. Thus, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites.

[0145] Multivalent Antibodies

[0146] In certain embodiments, the anti-CD19 antibody or its antigen-binding fragment described herein is present in a multivalent antibody. The speed of cellular internalization (and / or catabolism) of the antigen bound by the multivalent antibody expressed antibody can be faster than that of a bivalent antibody. The antibody described herein can be a multivalent antibody (e.g., a tetravalent antibody) having three or more antigen binding sites, which can be easily produced by recombinant expression of nucleic acids encoding antibody polypeptide chains. The multivalent antibody can include a dimerization domain and three or more antigen binding sites. An exemplary dimerization domain includes an Fc region or a hinge region (or is composed of an Fc region or a hinge region). The multivalent antibody can include three to about eight (e.g., four) antigen binding sites (or is composed of them). The multivalent antibody optionally includes at least one polypeptide chain (e.g., at least two polypeptide chains), wherein the polypeptide chain includes two or more variable domains. For example, the polypeptide chain may comprise VD1-(X1)n-VD2-(X2)n-Fc, wherein VD1 is the first variable domain, VD2 is the second variable domain, Fc is the polypeptide chain of the Fc region, X1 and X2 represent amino acids or peptide spacers, and n is 0 or 1.

[0147] Conjugated Antibodies

[0148] The antibodies disclosed herein may be conjugated antibodies bound to various molecules including macromolecular substances, such as polymers (e.g., polyethylene glycol (PEG), polyethyleneimine (PEI) modified with PEG (PEI-PEG), polyglutamic acid (PGA) (N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer), hyaluronic acid, radioactive materials (e.g., 90Y, 131I) fluorescent substances, luminescent substances, haptens, enzymes, metal chelates, drugs and toxins (e.g., calcheamicin, Pseudomonas aeruginosa exotoxin A, ricin (e.g., deglycosylated ricin A chain), and auristatins such as auristatin E and auristatin F).

[0149] In one embodiment, to improve the cytotoxic effect of anti-CD19 antibodies and thus improve their therapeutic effectiveness, antibodies are conjugated to highly toxic substances (including radioisotopes and cytotoxic agents). These conjugates can selectively deliver toxic loads to target sites (i.e., cells expressing antigens recognized by the antibody), while ignoring cells not recognized by the antibody. To minimize toxicity, conjugates are typically engineered based on molecules with short serum half-lives (thus using murine sequences, and IgG3 or IgG4 isotypes).

[0150] In certain embodiments, the anti-CD19 antibody or its antigen-binding fragment is modified by improving its stabilization and / or retention, for example, at least 1.5, 2, 5, 10 or 50 times in the circulation (e.g., in blood, serum or other tissues). For example, the anti-CD19 antibody or its antigen-binding fragment can be associated with a polymer, such as a substantially non-antigenic polymer, such as a polyoxyalkylene or polyethylene oxide (e.g., conjugated thereto). Suitable polymers will vary substantially by weight. A polymer having a molecular number average weight in the range of about 200 to about 35,000 (or about 1,000 to about 15,000 and 2,000 to about 12,500) daltons can be used. For example, an anti-CD19 antibody or its antigen-binding fragment can be conjugated to a water-soluble polymer, such as a hydrophilic polyethylene polymer, such as polyvinyl alcohol or polyvinyl pyrrolidone. Examples of such polymers include polyoxyalkylene homopolymers such as polyethylene glycol (PEG) or polypropylene glycol, polyoxyethylated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymer is maintained. Additional useful polymers include polyoxyalkylenes such as polyethylene oxide, polypropylene oxide, and block copolymers of polyethylene oxide and polypropylene oxide; polymethacrylates; carbomers; and branched or unbranched polysaccharides. The above-mentioned conjugated antibodies can be prepared by chemically modifying the antibodies described herein or low molecular weight forms thereof. Methods for modifying antibodies are well known in the art (e.g., US5,057,313 and US15 5,156,840).

[0151] Methods of producing antibodies

[0152] Antibodies can be produced in bacteria or eukaryotic cells. For example, some antibodies of Fab can be produced in bacterial cells such as Escherichia coli cells. Antibodies can also be produced in eukaryotic cells such as transformed cell lines (e.g., CHO, 293E, COS). In addition, antibodies (e.g., scFv) can be expressed in yeast cells such as Pichia (Pichia) (see, e.g., Powers et al., J Immunol Methods. 251: 123-35 (2001)), Hansenula or Saccharomyces. To produce related antibodies, polynucleotides encoding the antibodies are constructed, introduced into expression vectors, and then expressed in suitable host cells. Standard molecular biology techniques are used to prepare recombinant expression vectors, transfect host cells, select transformants, culture host cells and recover antibodies.

[0153] If the antibody is expressed in bacterial cells (e.g., E. coli), the expression vector should have features that allow the vector to be amplified in the bacterial cells. When E. coli HB101 or XL1-Blue is used as a host, the vector must have a promoter that allows efficient expression in E. coli, such as lacZ promoter (Ward et al., 341: 544-546 (1989), araB promoter (Better et al., Science, 240: 1041-1043 (1988)) or T7 promoter. Examples of such vectors include, for example, M13 series vectors, pUC series vectors, pBR322, pBluescript, pCR-Script, pGEX-5X-1 (Pharmacia), "QIAexpress system" (QIAGEN), pEGFP and pET (when using this expression vector, the host is preferably a T7 expression vector). The expression vector may contain a signal sequence for antibody secretion. For production in the extracellular cytoplasm of E. coli, the pelB signal sequence (Lei et al., J. Bacteriol., 169:4379 (1987)) can be used as a signal sequence for antibody secretion. For bacterial expression, the calcium chloride method or electroporation method can be used to introduce the expression vector into bacterial cells. If the antibody is to be expressed in animal cells such as CHO, COS and NIH3T3 cells, the expression vector includes a promoter required for expression in these cells, such as the SV40 promoter (Mulligan et al., Nature, 277:108 (1979)), the MMLV-LTR promoter, Promoter (Mizushima et al., Nucleic Acids Res., 18: 5322 (1990)) or CMV promoter. In addition to the nucleic acid sequence encoding immunoglobulin or its domain, the recombinant expression vector can carry additional sequences, such as sequences (such as replication origins) and selectable marker genes that regulate vector replication in host cells. Selectable marker genes help select host cells into which vectors have been introduced (see, for example, U.S. Patents No. 4,399,216, No. 4,634,665 and No. 5,179,017). For example, in a host cell into which a vector has been introduced, selectable marker genes generally confer resistance to drugs such as G418, hygromycin or methotrexate. Examples of vectors with selectable markers include pMAM, pDR2, pBK-RSV, pBKCMV, pOPRSV and pOP13.

[0154] In one embodiment, the antibody is produced in a mammalian cell. Exemplary mammalian host cells for expressing antibodies include Chinese hamster ovary (CHO cells) (including dhfr-CHO cells, which are described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77: 4216-4220, with, for example, DHFR selectable markers as described in Kaufman and Sharp (1982) Mol. Biol. 159: 601-621), human embryonic kidney 293 cells (e.g., 293, 293E, 293T), COS cells, NIH3T3 cells, lymphocytic cell lines (e.g., NS0 myeloma cells and SP2 cells), and cells from transgenic animals (e.g., transgenic mammals). For example, the cell is a mammary epithelial cell.

[0155] In an exemplary system for antibody expression, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain of an anti-CD19 antibody (e.g., dafamidis monoclonal antibody) is introduced into a dhfr-CHO cell by calcium phosphate-mediated transfection. In the recombinant expression vector, each of the antibody heavy chain and light chain genes is operably connected to an enhancer / promoter regulatory element (e.g., derived from SV40, CMV, adenovirus, etc., such as a CMV enhancer / AdMLP promoter regulatory element or an SV40 enhancer / AdMLP promoter regulatory element) to drive high-level gene transcription. The recombinant expression vector also carries the DHFR gene, which allows the use of methotrexate selection / amplification to select the CHO cells transfected with the vector. Cultivate the selected transformant host cell to allow the expression of antibody heavy chain and light chain, and recover the antibody from the culture medium. Antibodies can also be produced by transgenic animals. For example, U.S. Patent No. 5,849,992 describes a method for expressing antibodies in the mammary gland of a transgenic mammal. A transgenic is constructed, which includes a milk-specific promoter and a nucleic acid encoding a related antibody and a signal sequence for secretion. The milk produced by females of such transgenic mammals includes the relevant antibodies secreted therein. The antibodies can be purified from the milk, or used directly in some applications. Animals comprising one or more of the nucleic acids described herein are also provided.

[0156] The antibodies disclosed herein can be separated and purified as substantially pure and homogeneous antibodies from the inside or outside (e.g., culture medium) of the host cell. The method commonly used for antibody purification for separation and purification can be used for separation and purification of antibodies, and is not limited to any particular method. Antibodies can be separated and purified by appropriate selection and combination of column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis and recrystallization. Chromatography includes, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). Chromatography can be performed using liquid chromatography such as HPLC and FPLC. The column used for affinity chromatography includes protein A column and protein G column. The example of the column using protein A column includes Hyper D, POROS and Sepharose FF (GE Healthcare Biosciences). The present disclosure also encompasses antibodies that are highly purified using these purification methods.

[0157] Antibody pharmaceutical compositions and administration

[0158] The anti-CD19 antibodies or antigen-binding fragments thereof described herein can be formulated as pharmaceutical compositions for administration to a subject, for example, to treat the conditions described herein. Typically, the pharmaceutical composition includes a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carriers" include any and all solvents, dispersion media, coating agents, antibacterial and antifungal agents, isotonic agents, and absorption delay agents that are physiologically compatible. The composition may include a pharmaceutically acceptable salt, such as an acid addition salt or a base addition salt (see, for example, Berge, SM et al., (1977) J. Pharm. Sci. 66: 1-19).

[0159] Pharmaceutical formulation is a recognized art and is further described in, for example, Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th edition, Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th edition, Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd edition (2000) (ISBN: 091733096X).

[0160] The anti-CD19 antibody or antigen-binding fragment thereof can be administered to a subject, such as a subject in need thereof, such as a human subject, by a variety of methods.

[0161] For many applications, the route of administration is one of: intravenous injection or infusion (IV), subcutaneous injection (SC), intraperitoneal (IP), or intramuscular injection. Intraarticular delivery may also be used. Other parenteral modes of administration may also be used. In some cases, administration may be oral administration. The route and / or mode of administration of the antibody or antigen-binding fragment thereof may also be adapted to individual circumstances, for example, by monitoring the subject, for example, using tomographic imaging, for example, to observe a tumor.

[0162] The pharmaceutical composition may include a "therapeutically effective amount" of an anti-CD19 antibody or antigen-binding fragment thereof described herein. Such an effective amount may be determined within the boundaries of the dosages and dosing regimens disclosed herein, based on the effects of the administered agents, or if more than one agent is used, the combined effects of the agents. The therapeutically effective amount of an agent may also vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual, such as improving at least one parameter of the condition or improving the symptoms of at least one condition. A therapeutically effective amount is also an amount in which the therapeutically beneficial effects exceed any toxic or deleterious effects of the composition.

[0163] In certain embodiments, the anti-CD19 antibody replacing Dafasimab is a human, humanized or chimeric antibody. In another embodiment of the present disclosure, the anti-CD19 antibody replacing Dafasimab belongs to the IgG isotype. In another embodiment, the antibody replacing Dafasimab is an IgG1, IgG2 or IgG1 / IgG2 chimeric antibody. In another embodiment of the present disclosure, the anti-CD19 antibody isotype replacing Dafasimab is engineered to enhance antibody-dependent cell-mediated cytotoxicity. In another embodiment, the heavy chain constant region of the anti-CD19 antibody replacing Dafasimab comprises amino acids 239D and 332E, wherein the Fc numbering is according to the EU index as in Kabat. In another embodiment, the anti-CD19 antibody replacing Dafasimab is IgG1, IgG2 or IgG1 / IgG2, and the chimeric heavy chain constant region of the anti-CD19 antibody comprises amino acids 239D and 332E, wherein the Fc numbering is according to the EU index as in Kabat.

[0164] Table A: Dafacitinib (MOR208)

[0165]

[0166]

[0167] Example

[0168] Study: A Phase 1b / 2, open-label, multicenter study (MINDway) to evaluate the safety and pharmacokinetics of a modified IV dosing regimen of dafacilitation mab in combination with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R / RDLBCL).

[0169] To evaluate a dosing schedule of dafacitinib that provides approximately 50% less intravenous infusion than the currently approved drug schedule, the following modifications of the currently approved dosing schedule were defined:

[0170] Dosing frequency is planned to be reduced from once a week (QW) to once every two weeks (Q2W) starting from day 15 of cycle 1 (C1D15), and from Q2W to once every four weeks (Q4W) starting from C4D1

[0171] The first three infusions (i.e., Days 1, 4, and 8) are planned to maintain dafaximab at the previous dose level of 12 mg / kg; dafaximab dose levels will be increased starting on C1D15

[0172] Stepwise dose escalation was implemented as a risk minimization measure to limit AEs (e.g., IRR or tumor lysis syndrome [TLS]) that could occur soon after the start of treatment. Taking into account this new dosing schedule (see Table 2), the dalasimab POP-PK model was used to identify new dose levels that produced dalasimab trough values ​​similar to those observed in the pivotal clinical trial L-MIND to maintain the previously established exposure / efficacy relationship. 24 mg / kg and 30 mg / kg administered according to the dosing schedule outlined in Table 2 were identified as potential new dose levels tested in the current trial.

[0173] Comparison of predicted minimum concentrations (C) at the end of cycle 3 between the L-MIND, 12 / 24 mg / kg, and 12 / 30 mg / kg dosing schedules. 谷值 ) and the maximum concentration (C max ) values ​​and the box plots of the predicted area under the curve (AUC) levels (AUC28 and AUC56) after one and two treatment cycles are shown in Figure 1 and Figure 2 The model predictions showed that a dose of 30 mg / kg of dafacitinib was required to achieve C 谷值 In contrast, the predicted C 谷值 Levels were below L-MIND trough levels (reduction in geometric mean concentration relative to L-MIND: 2.9% for 12 / 30 mg / kg vs. 21.8% for 12 / 24 mg / kg).

[0174] Figure 3 Comparison of median model-predicted dalasimab concentrations over time between L-MIND and the target 12 / 30 mg / kg dosing regimen is shown and demonstrates that similar dalasimab C values ​​were achieved with the two different dosing schedules. 谷值 Additional details on the simulation can be found in MorphoSys report MOR208L050.

[0175] Additionally, simulations were used to compare expected exposures from the planned study of MOR208C115 with previous nonclinical safety studies and clinical studies:

[0176] In cynomolgus monkeys receiving a 100 mg / kg QW dose (i.e., at the NOAEL), the expected steady-state activity of dafacitinib is AUC0-144h and C max Approximately 6-7 times higher than R / R DLBCL patients dosed on the 12 / 24 mg / kg regimen, and approximately 5 times higher than patients dosed on the 12 / 30 mg / kg regimen

[0177] Compared with the clinical trial L-MIND, for 12 / 24mg / kg and 12 / 30mg / kg dosing, C max concentrations are expected to be 1.4-fold and 1.7-fold higher, respectively; compared to B-MIND, for 12 / 24 mg / kg and 12 / 30 mg / kg dosing, C max The concentrations are expected to be 1.2 and 1.4 times higher, respectively.

[0178] In summary, the 12 / 30 mg / kg dosing regimen represents a promising strategy based on similar C values ​​as in L-MIND. 谷值 However, in order to allow for the stepwise evaluation of increasing darfacitinib C max Patients enrolled in Cohort 1 will start with a 12 / 24 mg / kg dosing regimen if safety data supports further dose escalation, and a target 12 / 30 mg / kg dosing regimen will be studied in Cohort 2.

[0179] Benefit / risk assessment

[0180] The risk assessment of dalasimonab and LEN is based on data from nonclinical studies and clinical experience from completed and ongoing clinical trials. Dafacitinib monotherapy is well tolerated in R / RB cell lymphoma (BCL) (Jurczak et al., 2018). Similarly, dalasimonab plus LEN showed a manageable safety profile in R / R DLBCL in the L-MIND trial (Salles et al., 2020) and was approved by the FDA in the United States on July 31, 2020.

[0181] In June 2021, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a conditional marketing authorization for dalimibinib in combination with lenalidomide followed by dalimibinib monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

[0182] More detailed information on the known and expected benefits and risks of dafacitinib and reasonably anticipated AEs is available in the current version of the IB.

[0183] risk assessment

[0184] Dafacitinib is approved for use at a dose of 12 mg / kg. With the study dosing regimens (combinations of 12 / 24 mg / kg or 12 / 30 mg / kg) as shown in Table 2, a higher C of Dafacitinib than previously observed in L-MIND is expected. max Based on current nonclinical and clinical safety data, no correlation between AE incidence and exposure was observed (including C max ). Still, the C max The expected range of values ​​is higher than previous clinical data and is not covered by previous clinical data. In order to reduce the risk of potential AEs such as IRR and TLS that occur shortly after the start of treatment, all patients will maintain a dose of 12 mg / kg when the initial three dafasimab administrations of C1D1, C1D4 and C1D8 before the dose is increased to 24 mg / kg or 30 mg / kg. In addition, the infusion duration of the higher dafasimab dose will be doubled to maintain the dafasimab infusion rate (in mg / h) similar to that in L-MIND. Internal DSMC will monitor safety events during the study and determine dose changes based on emerging safety, pharmacokinetics and pharmacodynamics data. Based on the clinical experience of the combination of dafasimab and LEN from L-MIND, the most common side effects (≥20%) of dafasimab plus LEN are neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, fever, peripheral edema, respiratory tract infection and anorexia. Serious adverse events (SAEs) reported in ≥6% of patients included infections including pneumonia and febrile neutropenia.

[0185] At the first data cutoff point of October 10, 2022, two patients who were dosed at 24 mg / kg with doubled infusion duration (four hours) tolerated the infusion well and showed no significant IRR. One patient was dosed at 24 mg / kg over a 2-hour infusion duration and also tolerated the infusion without any significant IRR.

[0186] The modified dosing regimen (i.e., reducing the overall frequency of clinic visits by half) results in less burden on patients and supports long-term treatment adherence. In addition, the reduced hospital visits may reduce exposure to nosocomial infections in an already vulnerable patient population given the severity of the disease.

[0187] As shown in the L-MIND trial, the combination of dalasizumab plus LEN provides clinical benefit for patients with R / RDLBCL. Based on clinical efficacy data as of the data cutoff point of October 30, 2020, for patients whose DLBCL diagnosis was confirmed by central pathology, the combination of dalasizumab plus LEN showed an ORR of 53.5% (95% CI: 41.3; 65.5), and a CR rate of 35.2% (95% CI: 24.2; 47.5) and a median DoR of 43.9 months (95% CI: 15.0; no response [NR]). Compared to monotherapy with dalasizumab and LEN, an ORR of >50% is considered clinically highly significant in the relapsed and refractory setting of DLBCL that is not eligible for high-dose chemotherapy and ASCT. In addition, based on the characterized safety profile of LEN administered as a monotherapy, safety data from the L-MIND trial indicate that adding dalasizumab to LEN adds very little additional toxicity.

[0188] The new dosing regimen is expected to reduce patient burden while achieving the same trough levels as in L-MIND. In addition, the same clinical efficacy is expected. max values ​​(L-MIND relative to 12 / 24 mg / kg and 12 / 30 mg / kg predicted values), no new types of safety events are expected.

[0189] Goals, End Points, and Estimated Outcomes

[0190] The following objectives and endpoints will be evaluated in the study, see Table 1:

[0191] Table 1: Targets and corresponding endpoints

[0192]

[0193]

[0194] Abbreviation: C max = maximum concentration; C 谷值 = minimum concentration; DLBCL = diffuse large B-cell lymphoma; NK = natural killer; Q2W = every 2 weeks; Q4W = every 4 weeks; R / R = relapsed / refractory; TEAE = treatment-emergent adverse event. Each treatment cycle was 28 days.

[0195] Estimation results

[0196] The main clinical question of interest is: given the proposed alternative treatment dosing regimen of dafacitinib at higher doses than previously studied, what is the incidence and severity of treatment-emergent adverse events (TEAEs) observed in patients with R / R DLBCL who received at least one dose of 24 or 30 mg / kg? This will allow the safety and tolerability of the alternative treatment dosing regimen to be assessed. The main outcome estimates and their properties are described in Section 4. Possible intermittent events and strategies to capture them are described in Section 4.

[0197] Study Design

[0198] MOR208C115 (MINDway) is an open-label, multicenter Phase 1b / 2 study of dalasimonab in combination with lenalidomide (LEN) to evaluate a modified dalasimonab dosing regimen in adult patients with R / R DLBCL. Overall, approximately 51 patients will be enrolled in the study. Patients will receive LEN in combination with dalasimonab in 28-day cycles. The modified dalasimonab dosing regimen will be studied in a stepwise design with two sequential cohorts followed by an expansion cohort at the recommended dose level. Dalasimonab will be administered as an intravenous infusion according to the following dosing schedule (Table 2).

[0199] Table 2: Dosing schedule and frequency

[0200]

[0201] 1 Each treatment cycle lasts 28 days.

[0202] LEN (25 mg) will be administered for up to 12 cycles or until disease progression, unacceptable toxicity, withdrawal, death, or loss to follow-up, whichever comes first. After cycle 12 or discontinuation of LEN, patients will continue darfaxome monotherapy at the designated dosing regimen until disease progression, unacceptable toxicity, withdrawal, death, or loss to follow-up, whichever comes first. In this study, there will be no follow-up for overall survival after the end of treatment (EOT).

[0203] The Data and Safety Monitoring Committee (DSMC), composed of representatives of the sponsor and the investigators, will continue to monitor the study and may recommend stopping enrollment at any time based on emerging safety data. In addition, a scheduled DSMC meeting will be held when at least 6 patients have completed the 5-week (35-day) safety observation period in Group 1 and Group 2, respectively.

[0204] The specific responsibilities, composition, meeting format and frequency of the DSMC are outlined in the DSMC Charter.

[0205] Study Group

[0206] The study will enroll approximately 51 patients with a histologically confirmed diagnosis of R / R DLBCL (as specified in inclusion criterion 3) based on local pathology reports.

[0207] All patients must meet the eligibility criteria listed below to be included in the study. Prospectively approved deviations from the eligibility criteria, also known as protocol waivers or exemptions, are not permitted.

[0208] Inclusion criteria

[0209] Patients were eligible for inclusion in the described studies only if all of the following criteria applied:

[0210] 1. Ability to provide signed informed consent: Regulatory, ethical, and trial monitoring considerations, which include compliance with the requirements and limitations outlined in the Informed Consent Form (ICF) and this protocol.

[0211] 2. Patients must be between 18 and 80 years old (18 to 70 years old in the Czech Republic) at the time of signing the informed consent form.

[0212] 3. One of the following histologically confirmed diagnoses:

[0213] Not otherwise specified (NOS) DLBCL

[0214] T cell / histiocyte-rich large B cell lymphoma (THRLBCL)

[0215] Epstein-Barr virus (EBV)-positive DLBCL in the elderly (EBV-positive DLBCL)

[0216] Grade 3b follicular lymphoma

[0217] Combined lymphoma with a DLBCL component and subsequent relapse of DLBCL according to the Revised European and American Lymphoma / World Health Organization (REAL / WHO) classification.

[0218] Additionally, patients with evidence of histologic transformation to DLBCL from an earlier-diagnosed low-grade lymphoma (ie, indolent lesions such as follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia) with subsequent relapse of DLBCL were eligible.

[0219] 4. Tumor tissue must be available for retrospective central pathology review as an aid to participation in this study. If archived paraffin-embedded tumor tissue obtained ≤ 3 years prior to screening is not available, fresh tumor tissue samples should be obtained from the patient.

[0220] 5. The patient must:

[0221] a. Have relapsed and / or refractory disease as defined in Appendix 3: Study Specific Definitions Appendix

[0222] b. Have at least one site of disease that is measurable in two dimensions. At baseline, lesions must have a maximum transverse diameter of ≥1.5 cm and a maximum perpendicular diameter of ≥1.0 cm. Lesions must be positive on positron emission tomography (PET) scans (for definition see Juweid et al., 2007)

[0223] c. Received at least one, but no more than three, prior systemic regimens for the treatment of DLBCL, and one line of therapy must have included cluster of differentiation-20 (CD20)-targeted therapy (e.g., rituximab [RTX])

[0224] d. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

[0225] 6. Patients who are not eligible for intensive salvage therapy including autologous stem cell transplantation (ASCT) or are unwilling to undergo such therapy. The reason for patient ineligibility must meet one of the criteria described below and be recorded in the patient source data:

[0226] a. Inadequate physical status (Karnofsky physical status ≤ 80%; see Karnofsky physical status scale)

[0227] b. Disease is unresponsive to salvage chemotherapy. Responsiveness is defined as tumors showing a complete response (CR) or partial response (PR) to salvage chemotherapy

[0228] c. Inadequate major organ function (any of the following):

[0229] i. Symptomatic congestive heart failure

[0230] ii. Lung function - forced vital capacity (FVC), forced expiratory volume in 1 second (FEV-1) and corrected diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 60%

[0231] iii. Liver function - total serum bilirubin and transaminases > 2× upper limit of normal (ULN)

[0232] d. History or evidence of significant concurrent medical or psychiatric illness that would significantly compromise the patient's clinical care and chances of survival

[0233] e. Failure to collect sufficient stem cell transplants (e.g. <1-2×10 6 CD34+ cells without tumor contamination / kg recipient body weight)

[0234] 7. Patients must meet the following laboratory criteria at screening:

[0235] a. Absolute neutrophil count (ANC) ≥ 1.5 × 10 9 / L (unless secondary to bone marrow involvement of DLBCL as confirmed by recent bone marrow aspirate and biopsy)

[0236] b. Platelet count ≥75×10 9 / L (unless secondary to bone marrow involvement of DLBCL as confirmed by recent bone marrow aspirate and biopsy)

[0237] c. Total serum bilirubin ≤2.5×ULN unless secondary to Gilbert's syndrome or documented lymphomatous liver involvement. Patients with Gilbert's syndrome or documented lymphomatous liver involvement may be included if their total bilirubin is ≤5×ULN (see Exclusion Criterion 6g)

[0238] d. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3×ULN or < 5×ULN in the setting of documented liver involvement

[0239] e. Serum creatinine CL must be ≥ 50 mL / min measured or calculated using the standard Cockcroft and Gault formula

[0240] Exclusion criteria

[0241] Patients were excluded from the study if any of the following criteria applied:

[0242] 1. General Terms:

[0243] a. Patients admitted according to law or patients under judicial protection

[0244] b. Concurrent enrollment in another intervention clinical study

[0245] 2. Patients with the following conditions:

[0246] a. Any other histological type of lymphoma, including primary mediastinal (thymic) large B-cell (PMBL) or Burkitt's lymphoma

[0247] b. Primary refractory DLBCL (for definitions, see Appendix 3: Study-specific definitions)

[0248] c. Known "double / triple hit" genetics (high-grade B-cell lymphoma) characterized by simultaneous detection of MYC translocations with BCL2 and / or BCL6 as defined by fluorescence in situ hybridization. MYC, BCL2, BCL6 testing is not required prior to study entry

[0249] 3. Patients with the following conditions within 14 days prior to dosing on Day 1:

[0250] a. Not discontinued CD20-targeted therapy, chemotherapy, radiation therapy, investigational anticancer therapy, or other lymphoma-specific therapy

[0251] b. Underwent major surgery (within 4 weeks) or sustained a significant traumatic injury

[0252] c. Receive live virus vaccines (see Appendix 7: Covid-19: Infection Prevention and Vaccines)

[0253] d. Parenteral antimicrobial therapy is required for active episodic infections

[0254] 4. Patients with the following conditions:

[0255] a. In the investigator's opinion, has not adequately recovered from the adverse toxic effects of previous therapy

[0256] b. Prior use of CD19-targeted therapy or Treatment with thalidomide (eg, thalidomide, LEN)

[0257] c. Have resistance to dafacitinib, and / or history of hypersensitivity to compounds of similar biological or chemical composition to the excipients contained in the investigational therapeutic formulation

[0258] d. Underwent ASCT within ≤ 3 months before signing the ICF.

[0259] Patients with a more advanced history of ASCT were required to demonstrate complete hematologic recovery prior to study inclusion.

[0260] e. Has undergone previous allogeneic stem cell transplantation

[0261] f. Patients with a history of deep vein thrombosis / embolism, threatened thromboembolism, or known thrombophilia or who are at high risk for thromboembolic events in the opinion of the investigator and are unwilling / able to take venous thromboembolism (VTE) prophylaxis during the entire treatment period

[0262] g. Concurrent use of other anticancer or experimental treatments

[0263] 5. History of other malignant diseases that may affect compliance with the regimen or interpretation of results. Exceptions:

[0264] Patients with any malignancy that has been adequately treated with curative intent and has been in remission without treatment for >2 years prior to enrollment are eligible.

[0265] b. Patients with low-grade early prostate cancer (Gleason score 6 or less, stage 1 or 2) who did not require therapy at any time prior to the study are eligible 6. Patients with the following:

[0266] a. Positive hepatitis B and / or hepatitis C serology (see 12.8 Appendix 8: Hepatitis virus serology for details)

[0267] b. Known human immunodeficiency virus (HIV) seropositivity or history of active viral infection

[0268] c. Central nervous system (CNS) lymphoma involvement - current or past medical history

[0269] d. History or signs of clinically significant cardiovascular, CNS, and / or other systemic disease that, in the opinion of the investigator, would preclude participation in the study or impair the patient's ability to provide informed consent

[0270] e. History or signs of rare genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

[0271] f. Gastrointestinal (GI) abnormalities (absorption problems), including inability to take oral medications

[0272] g. History or signs of severe liver damage (total serum bilirubin >3 mg / dL), jaundice unless secondary to Gilbert's syndrome or documented lymphoma with liver involvement (see inclusion criteria 7c)

[0273] h. History of hypersensitivity to any of the study treatment or its excipients or to drugs of similar chemical class

[0274] i. Any other medical condition that, in the opinion of the investigator, makes the patient unsuitable for research.

[0275] 7. Contraception clause:

[0276] Females: Due to the teratogenic potential of LEN, FCBP must:

[0277] For all countries except the United States:

[0278] a. Not pregnant as confirmed by a negative serum pregnancy test at Screening and a medically supervised urine pregnancy test prior to initiation of study therapy

[0279] b. Avoid breastfeeding and egg donation during the study and for 3 months after the last dose of study drug or according to the local guidelines of the LEN, whichever is longer.

[0280] c. Agree to ongoing pregnancy testing during the study and after study treatment ends. This applies even if the patient is completely abstinent.

[0281] d. Commitment to continue to abstain from heterosexual intercourse for at least 4 weeks before starting study drug, during study treatment, and for 3 months after the last dose of study drug, or for LEN according to local guidelines, whichever is longer, if consistent with their lifestyle (must be reviewed monthly), or agree to use and be able to comply with the use of highly effective contraceptive measures without interruption

[0282] Applicable to the United States:

[0283] e. Not pregnant as confirmed by pregnancy test performed within 10-14 days before starting treatment and again within 24 hours of starting treatment (even if complete abstinence is chosen as a method of birth control)

[0284] f. Avoid breastfeeding and egg donation during the study and for 3 months after the last dose of study drug or per US guidelines of LEN, whichever is longer.

[0285] g. Agree to continue pregnancy testing during the course of the study (every 3 weeks in women with regular menstrual cycles and every 2 weeks in women with irregular menstrual cycles) and after the end of study treatment (even if complete abstinence is chosen as a method of birth control)

[0286] h. Do not become pregnant by using 2 effective methods of contraception simultaneously with each sexual intercourse with men: at least one highly effective method and one additional effective method, starting at least 4 weeks before study treatment, while taking study treatment, during breaks (dose interruptions), and for at least 3 months after stopping study treatment, or for LEN according to US guidelines, whichever is longer, while taking study treatment and for at least 3 months after the last dose of study treatment. Complete abstinence from heterosexual intercourse is also an acceptable method of contraception.

[0287] Emergency contraception is also allowed

[0288] 8. Male participants must:

[0289] For all countries except the United States:

[0290] a. If the patient is sexually active with FCBP, use an effective barrier method of contraception without interruption. Male patients should refrain from sperm donation during study participation and for 3 months after the last dose of study treatment, or according to local guidelines of the LEN, whichever is longer.

[0291] Applicable to the United States:

[0292] b. Use latex or synthetic condoms every time you have sex with a FCBP. Complete abstinence from heterosexual intercourse is also an acceptable method of contraception. The use of emergency contraception is also permitted. Male patients should refrain from sperm donation during study participation and for 3 months after the last dose of study drug, or according to US guidelines of LEN, whichever is longer.

[0293] Statistical analysis

[0294] The primary analysis will be conducted when all enrolled patients have completed C3D28 or discontinued the study for any reason before C3D28. The final analysis will be conducted at the end of the study.

[0295] Any deviations from the statistical analysis outlined in this protocol will be described in the clinical study report, with reasons for the deviations listed.

[0296] Details of the analyses to be performed on the data from this study will be provided in a separate SAP.

[0297] End of the study

[0298] The end of the study was defined as the date the last patient completed the last visit (approximately 3 years after the last patient received the first study treatment).

[0299] Upon study closure, MorphoSys will inform applicable regulatory authorities in accordance with local requirements.

[0300] Patient End-of-Study Visit: A patient's end-of-study visit was defined as the visit that occurred when the patient completed the 90-day safety follow-up after the last dalasizumab dose.

[0301] Appendix 3: Research Specific Definitions

[0302] For the purposes of this protocol, primary refractory disease was defined as disease that had progressed during first-line therapy according to the International Working Group response criteria (Cheson et al., 2007), and / or had a response less than PR to first-line therapy or disease relapse / progression <6 months from completion of first-line therapy.

[0303] Disease refractory to previous therapy is defined as a response of less than PR to the most recently administered systemic therapy.

[0304] Recurrent / progressive / recurrent disease reflects the appearance of any new lesion after the most recent systemic therapy or an increase of ≥50% from the nadir in a previously involved site according to the International Working Group Response Criteria (Cheson et al., 2007).

[0305] End of treatment: End of treatment is defined as the date the patient has received the last dose of dafacitinib. The end-of-treatment visit will be conducted within 14 days of the decision to discontinue treatment.

[0306] End of Study: The end of the study was defined as the date the last patient completed the last visit (approximately 3 years after the last patient received the first study treatment).

[0307] Patients' End-of-Study Visit: Patients' End-of-Study Visit was defined as when patients completed the 90-day safety follow-up after the last dalasizumab dose.

[0308] Initiation of a Study: Unless defined differently in the protocol, initiation of a clinical study means the first recruitment of potential subjects for a particular clinical study.

[0309] Appendix 7: Covid-19: infection prevention and vaccines

[0310] Patients must not have received live virus vaccines for this study. Killed inactivated vaccines, such as the injectable annual influenza vaccine, are permitted. Investigators should follow institutional guidelines regarding chemoprophylaxis of infection in patients deemed to be at high risk for infection.

[0311] When possible, relapsed / refractory patients who will be treated with immunosuppressive therapy including a dalasimab-containing regimen should begin vaccination against COVID-19 as soon as possible, at least the first dose, ideally approximately 2 weeks before the start of study treatment.

[0312] Based on current safety / benefit considerations and in the absence of contrary data or guidelines, we recommend that all patients with lymphoma should receive the COVID-19 vaccine (unless specifically contraindicated), accepting that this may not result in complete protection due to diminished humoral and / or cellular immunity.

[0313] For patients already on a dallasimab-containing regimen, the advantages and disadvantages of delaying vaccination to allow immune recovery or interrupting therapy need to be carefully considered on a case-by-case basis. Although it is possible that the COVID-19 vaccine will not produce a fully protective immune response, vaccination is recommended for these patients.

[0314] Appendix 8: Hepatitis virus serology

[0315] Patients will have hepatitis B and hepatitis C serology tested based on SoA. Hepatitis B biomarkers include HBsAg, total anti-hepatitis B core antibody (anti-HBc), and anti-HBsAb).

[0316] Only patients with a positive anti-HBc test who do not have detectable HBV DNA may be included. In these patients only, HBV DNA should be assessed at various follow-up visits as outlined in the SoA.

[0317] In the context of exclusion criteria, HBV seropositivity or HBV active viral infection means:

[0318] HBV surface antigen positive

[0319] HBV surface antigen negative, HBV surface antibody positive and / or HBV core antibody positive and detectable viral DNA. Note: Patients with HBV surface antigen negative and viral DNA negative are eligible

[0320] Patients who present with a classic vaccination profile of HBV surface antibody positive, HBV core antibody negative, and HBV surface antigen negative are eligible

[0321] If HBV-DNA becomes detectable during treatment, patients should be treated with prophylaxis against CD20 antibodies such as RTX according to local medical practice or institutional guidelines and followed for potential reactivation of hepatitis B. If HBV-DNA is positive, patients may remain in the study only if they are evaluated by a physician experienced in treating hepatitis B and prior treatment is started if deemed appropriate and / or according to local practice / guidelines.

[0322] Hepatitis C serology is performed only at screening. Hepatitis C biomarkers include anti-HCV antibodies. For patients who are anti-HCV antibody positive, HCV-RNA should be measured.

[0323] 1. A positive hepatitis C test is defined as a positive HCV antibody test and a positive HCV RNA test.

Claims

1. An anti-CD19 antibody for use in treating cancer, wherein the anti-CD19 antibody is administered at a dose of at least 24 mg / kg.

2. The anti-CD19 antibody for use according to claim 1, wherein the anti-CD19 antibody comprises a heavy chain variable region comprising a HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), a HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), and a HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3); and a light chain variable region comprising a LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), a LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and a LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).

3. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises a heavy chain variable region comprising a HCDR1 region of SYVMH (SEQ ID NO: 1), a HCDR2 region of NPYNDG (SEQ ID NO: 2), and a HCDR3 region of GTYYYGTRVFDY (SEQ ID NO: 3); and a light chain variable region comprising a LCDR1 region of RS SKSLQNVNGNTYLY (SEQ ID NO: 4), a LCDR2 region of RMSNLNS (SEQ ID NO: 5), and a LC DR3 region of MQHLEYPIT (SEQ ID NO: 6).

4. An anti-CD 19 antibody for use according to any one of the preceding claims, wherein the anti-CD 19 antibody comprises a heavy chain variable region of EVQLVESGGGLVKPGGSLKLSCAASGYTFTSY VMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (SEQ ID NO: 7) and a light chain variable region of DIVMTQSPATLSLSPGERATLSCR SSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSG SGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 8).

5. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises an Fc domain comprising an amino acid substitution at position S239 and / or I332, wherein the numbering is according to the EU index as in Kabat.

6. An anti-CD 19 antibody for use according to any one of the preceding claims, wherein the anti-CD 19 antibody comprises an Fc domain comprising an S239D amino acid substitution and an I332E amino acid substitution, wherein numbering is according to the EU index as in Kabat.

7. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody comprises ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:9) and the light chain constant region of RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:10).

8. An anti-CD 19 antibody for use according to any one of the preceding claims, wherein the anti-CD 19 antibody comprises EVQLVESGGGLVKPGGSLKLSCAASGYTFTSY VMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPD VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ The heavy chain region and DIVMTQSPAT of IDNO:11) LSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ The light chain region of ID NO:12).

9. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody is administered intravenously by intravenous infusion or subcutaneously.

10. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the dosage reduces the frequency of administration from once a week to at least once every two weeks.

11. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the cancer is a hematological malignancy.

12. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the cancer is lymphoma or leukemia.

13. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the cancer is non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or acute lymphoblastic leukemia (ALL).

14. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or relapsed or refractory diffuse large B-cell lymphoma (r / r DLBCL).

15. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody is administered once a week, once every two weeks or once every four weeks.

16. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody is administered at a dose ranging between 24 mg / kg and 30 mg / kg.

17. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody is administered at a dose of 24 mg / kg.

18. The anti-CD19 antibody for use according to any one of claims 1 to 16, wherein the anti-CD19 antibody is administered at a dose of 30 mg / kg.

19. An anti-CD19 antibody for use according to any one of claims 1 to 15, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on day 1, day 4 and day 9 of the first cycle, and a dose of at least 24 mg / kg is administered on day 15 of the first cycle; b) a dose of at least 24 mg / kg is administered on day 1 and day 15 of cycles 2-3; and c) a dose of at least 24 mg / kg is administered on day 1 of other subsequent cycles.

20. An anti-CD19 antibody for use according to any one of claims 1-15, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on day 1, day 4 and day 9 of the first cycle, and a dose ranging from 24 mg / kg to 30 mg / kg is administered on day 15 of the first cycle; b) a dose ranging from 24 mg / kg to 30 mg / kg is administered on day 1 and day 15 of cycles 2-3; and c) a dose ranging from 24 mg / kg to 30 mg / kg is administered on day 1 of other subsequent cycles.

21. An anti-CD19 antibody for use according to any one of claims 1 to 15, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on day 1, day 4 and day 9 of the first cycle, and a dose of 24 mg / kg is administered on day 15 of the first cycle; b) a dose of 24 mg / kg is administered on day 1 and day 15 of cycles 2-3; and c) a dose of 24 mg / kg is administered on day 1 of other subsequent cycles.

22. An anti-CD19 antibody for use according to any one of claims 1 to 15, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on day 1, day 4 and day 9 of the first cycle, and a dose of 30 mg / kg is administered on day 15 of the first cycle; b) a dose of 30 mg / kg is administered on day 1 and day 15 of cycles 2-3; and c) a dose of 30 mg / kg is administered on day 1 of other subsequent cycles.

23. An anti-CD19 antibody for use according to any one of the preceding claims, wherein the anti-CD19 antibody is administered in combination with lenalidomide.

24. A method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an anti-CD 19 antibody, wherein the anti-CD 19 antibody is administered at a dose of at least 24 mg / kg.

25. The method of claim 24, wherein the anti-CD19 antibody comprises a heavy chain variable region comprising a HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), a HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), and a HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3); and a light chain variable region comprising a LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), a LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and a LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).

26. The method of claim 24, wherein the anti-CD19 antibody comprises a heavy chain variable region comprising a HCDR1 region of SYVMH (SEQ ID NO: 1), a HCDR2 region of NPYNDG (SEQ ID NO: 2), and a HCDR3 region of GTYYYGTRVFDY (SEQ ID NO: 3); and a light chain variable region comprising a LCDR1 region of RSSKSLQNVNGNTYLY (SEQ ID NO: 4), a LCDR2 region of RMSNLNS (SEQ ID NO: 5), and a LCDR3 region of MQHLEYPIT (SEQ ID NO: 6).

27. The method of claim 24, wherein the anti-CD 19 antibody comprises a heavy chain variable region of EV QLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLE WIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (SEQ ID NO: 7) and a light chain variable region of DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTY LYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 8).

28. The method of any one of claims 24-27, wherein the anti-CD 19 antibody comprises an Fc domain comprising an amino acid substitution at position S239 and / or I332, wherein numbering is according to the EU index as in Kabat.

29. The method of any one of claims 24-27, wherein the anti-CD 19 antibody comprises an Fc domain comprising an S239D amino acid substitution and an I332E amino acid substitution, wherein numbering is according to the EU index as in Kabat.

30. The method of any one of claims 24-29, wherein the anti-CD 19 antibody comprises a heavy chain constant region of ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 9) and RT The light chain constant region of VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC (SEQ ID NO: 10).

31. The method of claim 24, wherein the anti-CD 19 antibody comprises EV QLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTIS KTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ The heavy chain region of ID NO:11) and DIVMTQSPATLSLSPGERATLSCRS SKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ The light chain region of IDNO:12).

32. The method of any one of claims 24-31, wherein the anti-CD 19 antibody is administered intravenously by intravenous infusion or subcutaneously.

33. The method of any one of claims 24-32, wherein the dosage reduces the frequency of dosing from once a week to at least once every two weeks.

34. The method of any one of claims 24-33, wherein the cancer is a hematological malignancy.

35. The method of any one of claims 24-33, wherein the cancer is lymphoma or leukemia.

36. The method of any one of claims 24-33, wherein the cancer is non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute lymphoblastic leukemia (ALL).

37. The method of any one of claims 24-33, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or relapsed or refractory diffuse large B-cell lymphoma (r / r DLBCL).

38. The method of any one of claims 24-37, wherein the anti-CD 19 antibody is administered once a week, once every two weeks, or once every four weeks.

39. The method of any one of claims 24-38, wherein the anti-CD 19 antibody is administered at a dose ranging between 24 mg / kg to 30 mg / kg.

40. The method of any one of claims 24-38, wherein the anti-CD 19 antibody is administered at a dose of 24 mg / kg.

41. The method of any one of claims 24-38, wherein the anti-CD 19 antibody is administered at a dose of 30 mg / kg.

42. The method of any one of claims 24-38, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on Day 1, Day 4, and Day 9 of the first cycle, and a dose of at least 24 mg / kg is administered on Day 15 of the first cycle; b) a dose of at least 24 mg / kg is administered on Day 1 and Day 15 of Cycles 2-3; and c) a dose of at least 24 mg / kg is administered on Day 1 of other subsequent cycles.

43. The method of any one of claims 24-38, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on Day 1, Day 4, and Day 9 of the first cycle, and a dose ranging from 24 mg / kg to 30 mg / kg is administered on Day 15 of the first cycle; b) a dose ranging from 24 mg / kg to 30 mg / kg is administered on Day 1 and Day 15 of Cycles 2-3; and c) a dose ranging from 24 mg / kg to 30 mg / kg is administered on Day 1 of other subsequent cycles.

44. The method of any one of claims 24-38, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on Day 1, Day 4, and Day 9 of the first cycle, and a dose of 24 mg / kg is administered on Day 15 of the first cycle; b) a dose of 24 mg / kg is administered on Day 1 and Day 15 of Cycles 2-3; and c) a dose of 24 mg / kg is administered on Day 1 of other subsequent cycles.

45. The method of any one of claims 24-38, wherein the anti-CD19 antibody is administered in a 28-day cycle, wherein: a) a dose of 12 mg / kg is administered on Day 1, Day 4, and Day 9 of the first cycle, and a dose of 30 mg / kg is administered on Day 15 of the first cycle; b) a dose of 30 mg / kg is administered on Day 1 and Day 15 of Cycles 2-3; and c) a dose of 30 mg / kg is administered on Day 1 of other subsequent cycles.

46. ​​The method of any one of claims 24-45, wherein the anti-CD 19 antibody is administered in combination with lenalidomide.